|
|
MVI Vaccine Development PortfolioMVI is providing support to promising malaria vaccine development projects. MVI works with partners in Africa, Australia, and Europe as well as the United States and India. The MVI portfolio includes a diversity of vaccine candidates, three of which have entered clinical development. Click on a project title to read additional information. We will update this list as new projects are signed. Initial Safety and Test-of-Concept Trial of Plasmodium falciparum Sporozoite (PfSPZ) VaccineObjective: To manufacture a vaccine consisting of purified, radiation-attenuated PfSPZ and conduct an initial safety and test-of-concept trial among volunteers in the United States. Lead Partner: Sanaria, Inc (Rockville, USA) Additional Partners: Navy Medical Research Center (NMRC) and University of Maryland Center for Vaccine Development (CVD) Agreement duration: 2006 - 2010 (39 months) MVI Vaccine Project Team Leader: Laurence Lemiale
Development and Evaluation of Adenovirus-vectors for a Malaria VaccineObjective: To assess the feasibility of including five optimized genes for Plasmodium falciparum malaria antigens in adenovirus-vectors. Lead Partner: GenVec Inc. (Gaithersburg, Maryland) Additional Partner: US Naval Medical Research Center (Silver Spring, Maryland) Agreement Duration: 2004 – 2007 MVI Vaccine Project Team Leader: Emily Locke Pediatric Clinical Development of RTS,S/AS02A Malaria VaccineObjective: To demonstrate the safety, immunogenicity, and protective efficacy of RTS,S—a pre-erythrocytic malaria vaccine candidate—in children in endemic countries. Lead Partner: GSK Bio (Rixensaart, Belgium) Clinical Trial Partners: UK Medical Research Council (The Gambia), Centro de Investigaçao em Saude de Manhiça (Manhiça, Mozambique), University of Barcelona (Barcelona, Spain), Ifakara Health Research Development Centre (Dar es Salaam, Tanzania), Swiss Tropical Institute (Basel, Switzerland), National Institute for Medical Research (Dar es Salaam, Tanzania), Joint Malaria Programme (Tanga, Tanzania), London School of Hygiene and Tropical Medicine (London, UK), University of Copenhagen (Copenhagen, Denmark), Albert Schweitzer Hospital (Lambaréné, Gabon), University of Tübingen (Tübingen, Germany), Kenya Medical Research Institute Wellcome Collaborative Research Programme (Kilifi, Kenya), Kumasi Center for Collaborative research (Kumasi, Ghana), School of Medical Sciences, Kwame Nkrumah University of Science and Technology (Kumasi, Ghana), The Kintampo Health Research Center (Kintampo, Ghana), Ghana Health Services (Accra, Ghana), Agogo Presbytarian Hospital (Agogo, Ghana) Agreement Duration: 2001 – 2010 MVI Vaccine Project Team Leader: Barbara Savarese Development of MSP1-42 and AMA-1Objective: To enable the National Institute of Allergy and Infectious Diseases’ (NIAID’s) Malaria Vaccine Development Branch (MVDB) to conduct initial human clinical safety trials of the AMA-1 P. falciparum blood stage antigens. Lead Partner: National Institutes of Health/NIAID/MVDB (Bethesda, Maryland) Additional Partners: WRAIR Pilot Lot Production Facility (Forest Glen, Maryland), Amgen Inc. (Thousand Oaks, California) Agreement Duration: 2001 – 2008 MVI Vaccine Project Team Leader: Elissa Malkin Development and Initial Clinical Testing of P. vivax Duffy Binding ProteinObjective: To conclude pre-clinical development, manufacture under current Good Manufacturing Practices (cGMP) conditions, and conduct initial human clinical safety trials on the PvRII fraction of the P. vivax Duffy Binding Protein. Lead Partner: International Centre for Genetic Engineering and Biotechnology (New Delhi, India) Additional Partner: Bharat Biotech International (Hyderabad, India) Agreement Duration: 2001 – 2007 MVI Vaccine Project Team Leader: Laurence Lemiale Development of MSP-2 as a Vaccine Against P. falciparumObjectives: To support the process development, cGMP manufacture, and formulation of MSP-2 (3D7 and FC27) as malaria vaccines and to demonstrate the safety and immunogenicity of the MSP2 formulations in a Phase 1 clinical trial in healthy malaria-naïve adults. Lead Partner: LaTrobe University (Melbourne, Australia) Additional Partners: GroPep, Ltd. (Adelaide, Australia), Royal Brisbane Hospital (Brisbane, Australia) Agreement Duration: 2001 – 2007 MVI Vaccine Project Team Leader: Paul Fahey Pre-clinical Development and Manufacture of MSP-4 and MSP-5Objective: To complete all pre-clinical development including preparation of regulatory documentation for two recombinant protein vaccine candidates based on merozoite surface antigens (MSP-4 and MSP-5). Lead Partner: Monash University (Clayton, Australia) Additional Partner: CSL Limited (Melbourne Australia) Agreement Duration: 2001 – 2007 MVI Vaccine Project Team Leader: Paul Fahey Partner LinksAlbert Schweitzer Hospital: www.uni-tuebingen.de
|
